Founded in Paris in 1920, Gide is a leading international law firm with 12 offices spread throughout the world.
Gide is physically present in six regions of the world, with 11 offices, enabling it to act on cases globally.
31 October 2024
Deals | France | Banking & Finance
Gide advised the biopharmaceutical company Inventiva, a company listed on Euronext Paris and Nasdaq, in an immediate financing of €94.1 million and up to €348 million, subject to satisfaction of conditions, from both new and existing investors.
The proceeds from this capital increase is intended to be primarily used to advance Inventiva’s Phase 3, NATiV3 clinical trial evaluating lanifibranor in patients with metabolic dysfunction-associated steatohepatitis (“MASH”).
The Gide team comprises partner Arnaud Duhamel with Aude-Laurène Dourdain, Mélanie Simon-Giblin, Elise Raymond and Mariléna Gryparis on the capital markets aspects; partner Didier Martin and Abel Colomb, on the corporate aspects and by Cooley LLP on U.S. law matters.
Gibson Dunn acted as French and U.S. counsel to the three lead investors and Davis Polk as U.S. counsel to the placement agents comprising J.P. Morgan, TD Cowen, Guggenheim Securities, and LifeSci Capital.
